Delving into the Latest Updates on Ethinyl Estradiol/Norgestimate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ethinylestradiol/norgestimate oral, NORGESTIMATE/ETHINYL ESTRADIOL, Ortho Tri-Cyclen

+ [18]

Target

ER x PR

Action

agonists

Mechanism

ERs agonists(Estrogen receptors agonists), PR agonists(Progesterone receptor agonists)

Therapeutic Areas

Other Diseases

Active Indication

Contraception

Inactive Indication

HemorrhageMetrorrhagia

Originator Organization

Johnson & Johnson

Active Organization

Ortho-McNeil Pharmaceutical LLC

Inactive Organization

McNeil Consumer & Specialty Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc.Johnson & Johnson Pharmaceutical Research & Development LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1989),

Contraception

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC43H55NO5

InChIKeyGYMWQLRSSDFGEQ-CXNPBKRFSA-N

CAS Registry79871-54-8

Specificity is one of the main tasks in reliable validation of anal. methods.Experience has shown that this problem is often treated rather formally in the case of using chromatog. methods for the determination of organic impurities so that the specificity of a proposed method is not fully proven.This article discusses key points for reliable assessment of the specificity of methods used for determining impurities.Practical recommendations and numerical values for decision making are given.The specificity of a method must be tested by conducting stress testing in such a way that the given API under stress degrades, i.e., the content of drug in the primary substance decreases, by greater than 0.5%.This is necessary at a min. for noticing the growth of existing impurities in the API and the formation of new impurities.On the other hand, the API degradation should not exceed 2% under oxidative stress and photodegradation conditions and should not exceed 5% for other stress factors (so as to minimize secondary reactions).The condition of permissible overlap of impurity peaks in the validation of method specificity has been substantiated as follows: the peak-to-valley (p/v) ratio should be ≥1.5 for overlapping impurity peaks.This is usually sufficient for ensuring reproducibility of the overlapping peak areas.If the overlapping peaks are close in height, then the p/v ratio can be <1.5 provided that the relative standard deviation of the area of overlapping peaks does not exceed 6% for successive injections (RSD ∼ 6%).This condition corresponds to a baseline signal-to-noise ratio S/N = 10, i.e., the limit of quantification.Issues related to validation of the specificity of methods for determining impurities in combined drugs are considered.

01 Jun 2019·Journal of applied physiology (Bethesda, Md. : 1985)Q3 · MEDICINE

Menstrual cycle-associated modulations in neuromuscular function and fatigability of the knee extensors in eumenorrheic women

Q3 · MEDICINE

Article

Author: Hicks, Kirsty M. ; Hunter, Sandra K. ; Brownstein, Callum G. ; Howatson, Glyn ; Simoes, Davina C. M. ; Goodall, Stuart ; Ansdell, Paul ; Škarabot, Jakob ; Thomas, Kevin

Sex hormone concentrations of eumenorrheic women typically fluctuate across the menstrual cycle and can affect neural function such that estrogen has neuroexcitatory effects, and progesterone induces inhibition. However, the effects of these changes on corticospinal and intracortical circuitry and the motor performance of the knee extensors are unknown. The present two-part investigation aimed to 1) determine the measurement error of an exercise task, transcranial magnetic stimulation (TMS)-, and motor nerve stimulation (MNS)-derived responses in women ingesting a monophasic oral contraceptive pill (hormonally-constant) and 2) investigate whether these measures were modulated by menstrual cycle phase (MCP), by examining them before and after an intermittent isometric fatiguing task (60% of maximal voluntary contraction, MVC) with the knee extensors until task failure in eumenorrheic women on days 2, 14, and 21 of the menstrual cycle. The repeatability of neuromuscular measures at baseline and fatigability ranged between moderate and excellent in women taking the oral contraceptive pill. MVC was not affected by MCP ( P = 0.790). Voluntary activation (MNS and TMS) peaked on day 14 ( P = 0.007 and 0.008, respectively). Whereas corticospinal excitability was unchanged, short-interval intracortical inhibition was greatest on day 21 compared with days 14 and 2 ( P < 0.001). Additionally, time to task failure was longer on day 21 than on both days 14 and 2 (24 and 36%, respectively, P = 0.030). The observed changes were larger than the associated measurement errors. These data demonstrate that neuromuscular function and fatigability of the knee extensors vary across the menstrual cycle and may influence exercise performance involving locomotor muscles. NEW & NOTEWORTHY The present two-part study first demonstrated the repeatability of transcranial magnetic stimulation- and electrical motor nerve stimulation-evoked variables in a hormonally constant female population. Subsequently, it was demonstrated that the eumenorrheic menstrual cycle affects neuromuscular function. Changing concentrations of neuroactive hormones corresponded to greater voluntary activation on day 14, greater intracortical inhibition on day 21, and lowest fatigability on day 21. These alterations of knee extensor neuromuscular function have implications for locomotor activities.

01 Aug 2018·Hormones & cancerQ3 · MEDICINE

The Impact of Hormonal Contraceptives on Breast Cancer Pathology

Q3 · MEDICINE

Article

Author: Hu, Hai ; Shriver, Craig D ; Dorchak, Jesse A ; Duensing, Anette ; Iida, Joji ; Cavanaugh, Jane ; Witt-Enderby, Paula A ; Deyarmin, Brenda ; Somiari, Stella ; Maria, Sifat ; Guarinoni, Joseph L

This retrospective case series study, using data obtained through questionnaires and histopathological diagnoses from 656 patients enrolled in the Department of Defense (DoD) Clinical Breast Care Project (CBCP), evaluated associations between hormonal contraceptive use and breast cancer pathology including benign breast pathologies. Three combination hormonal contraceptive agents (COCs) Lo Ovral (LO), Ortho Novum (ON), and Ortho Tri-Cyclen (OTC) were evaluated as they represented the most commonly used hormonal contraceptives in our cohort. The results of this study suggest that the ever use of LO + ON + OTC does not influence the overall incidence of benign breast condition or malignant disease compared to other COCs; however, patients that have used OTC had an association with a diagnosis of benign or luminal A pathologies whereas ON was associated with a diagnosis of benign and DCIS; LO showed no association with any diagnosis-benign or malignant. Patients that have used LO or ON were more likely to be diagnosed with breast cancer at age ≥ 40 years whereas patients that had ever used OTC were likely to be diagnosed before the age of 40. Caucasians were less likely to have used OTC and more likely to have used ON; however, use of either hormonal agent positively correlated with premenopausal status at diagnosis and having a benign condition. Age at diagnosis, ethnicity, BMI, family history, menstruation status, and duration of use were all independent predictors of different histopathological subtypes. We conclude that patient-specific variables should be considered when deciding on which type of hormonal contraceptive to use to minimize the risk of developing breast cancer or a breast-related pathology.

1

News (Medical) associated with Ethinyl Estradiol/Norgestimate

04 Mar 2021

·www.biospace.com

Mayne Pharma launches another generic oral contraceptive

ADELAIDE, Australia, March 4, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US. This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN® 24 FE, ORTHO CYCLEN® and ORTHO TRI-CYCLEN®. According to IQVIA, the annual US market sales for the four products were approximately US$315 million in the twelve months ending January 2021[1]. Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives. Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options. The four new products launched this year were sourced from the strategic partnership with Novast Laboratories." "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS™ (E4/DRSP) and a generic version of NUVARING®. NEXTSTELLIS which has a FDA target action date in April contains a new estrogen called estetrol or E4 in combination with a progestin, drospirenone. If approved, E4 will be the first new estrogen introduced in the US for contraceptive use in approximately 50 years." About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, offering patients better and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds. LOESTRIN® 24 FE, NEXTSTELLIS™, NUVARING®, ORTHO-CEPT®, ORTHO CYCLEN® and ORTHO TRI-CYCLEN® are registered trademarks of third parties. [1] IQVIA, MAT Sales and NSP Units for brand and generic equivalents, January 2021 Company Codes: Australia:MYX, OTC-PINK:MYPHY

Collaborate

100 Deals associated with Ethinyl Estradiol/Norgestimate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G03AA11 G03AB09	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Contraception	United States	Janssen Pharmaceuticals, Inc.	29 Dec 1989

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhage	Phase 2	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	01 Nov 2003
Metrorrhagia	Phase 2	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	01 Nov 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAN2019	Phase 1	-	22	Ubrogepant 50 mg	quhcropryg(barzwfeait) = Most (18/21) drug-related adverse events were related to ubrogepant and were mild iwumjvrfdd (rarezgfjji ) View more	Positive	09 Apr 2019
				Ortho-Cyclen (ethinyl estradiol/norgestimate)
NCT01475513 (CTgov)	Phase 4	Insulin Resistance	47	Ortho Cyclen® (African-American Women)	catriwlaxy(efjyvzzmoj) = lctbpbsqca zruxjeyqcc (bwojmtioac, mguevlldbo - llvtztjbxx) View more	-	10 Jul 2018
				Ortho Cyclen® (Caucasian Women)	catriwlaxy(efjyvzzmoj) = tvteuvxnbq zruxjeyqcc (bwojmtioac, myjkhtwajh - ubsvnuhmdg) View more
NCT00775190 (CTgov)	Not Applicable	Contraception	12	ortho tricyclen (Ortho Tricyclen™)	jpfmgoygvo(ofrfxfwstx) = enskgaemqb hefjanpcjr (nrtabxojrd, wmxfnimsct - ljkcrvdgxp) View more	-	17 Apr 2017
				Trinessa (Trinessa™)	jpfmgoygvo(ofrfxfwstx) = rliocovxjv hefjanpcjr (nrtabxojrd, lafvetrlhw - sctkmtkwho) View more
NCT01466673 (CTgov)	Phase 4	Acne Vulgaris	201	Ethinyl estradiol/Norgestimate (EE/NGM) (Ethinyl Estradiol/Norgestimate (EE/NGM))	higtgmowwz(mjuzgzonyn) = zgeayhiuhd ptapmqzcyv (hmnxonkvvo, 6.45) View more	-	19 Jun 2013
				Ethinyl estradiol/Desogestrel (EE/DSG) (Ethinyl Estradiol/Desogestrel (EE/DSG))	higtgmowwz(mjuzgzonyn) = jbegggpjis ptapmqzcyv (hmnxonkvvo, 7.58) View more
NCT00635570 (ACCEPT, CTgov)	Phase 4	Contraception	273	NuvaRing (Contraceptive Vaginal Ring)	lembubfbsc = whzgvaeryj cbjamaauue (asiqtcyojh, jhjshstewh - cqjykpsbdu) View more	-	07 Nov 2012
				Ortho Tri-cyclen Lo (Oral Contraceptive Pill)	lembubfbsc = dvetowaeak cbjamaauue (asiqtcyojh, eenugaruyd - ycqscaacnf) View more
NCT00205504 (Pubmed \| Fertil Steril)	Phase 4	-	46	combined hormonal oral contraceptive (Lean women)	ajbqmjajyw(kjgfvmvuvz) = glwhoalnmz ojfvkejpmu (sutiarzfyf )	-	01 Aug 2011
				combined hormonal oral contraceptive (Obese women)	ajbqmjajyw(kjgfvmvuvz) = keqegnzyiy ojfvkejpmu (sutiarzfyf )